BS PHARM KOREA Strengthens INHILO+ Market Development Through Distribution and Clinical Collaboration

PartnershipINHILO+Positive

AI Analysis

Summary

BS PHARM KOREA announced a distribution partnership with Dongkook Pharmaceutical and an ongoing clinical evaluation program for INHILO+, a dual-molecular HA skin booster, to strengthen its market development in South Korea.

Clinical Trial Data

Outcome Details

Distribution agreement with Dongkook Pharmaceutical and ongoing clinical evaluation program in South Korea

Importance:4/10

Sentiment:

0.50

partnershipdistributionclinical_collaborationskin_careSouth Koreadual-molecular_technology

Related Companies

$MOLN

Read the original article

Published by PR Newswire Biotech on September 6, 2026 12:00 PM

Read Original